www.chiesigroup.com Guest

Clenil (beclomethasone dipropionate) is one of Chiesi’s historical products and has been well consolidated on the market ever since its launch in Italy in 1979.

Clenil is indicated for the treatment of asthma, allergies, and other respiratory pathologies. It is the most versatile drug in our portfolio because it is available in various formulations: pressurised Metered-Dose Inhalers (pMDI), Unit Dose Vials (UDV), and Dry Powder Inhalers (DPI).

The pMDI formulation uses Chiesi patented Modulite technology.

This technology allowed the drug to achieve important results in European countries such as the United Kingdom, where sales and market share registered constant growth during the entire year. Due to its extraordinary therapeutic properties, is one of our most important resources still today.